- Home
- STRO vs DALN Comparison
STRO vs DALN Comparison
Compare STRO & DALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- DALN
- Stock Information
- Founded
- STRO 2003
- DALN 1954
- Country
- STRO United States
- DALN United States
- Employees
- STRO N/A
- DALN N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- DALN Newspapers/Magazines
- Sector
- STRO Health Care
- DALN Consumer Discretionary
- Exchange
- STRO Nasdaq
- DALN Nasdaq
- Market Cap
- STRO 77.7M
- DALN 73.2M
- IPO Year
- STRO 2018
- DALN 2008
- Fundamental
- Price
- STRO $0.88
- DALN $14.80
- Analyst Decision
- STRO Hold
- DALN
- Analyst Count
- STRO 7
- DALN 0
- Target Price
- STRO $3.97
- DALN N/A
- AVG Volume (30 Days)
- STRO 513.9K
- DALN 374.0K
- Earning Date
- STRO 08-12-2025
- DALN 08-05-2025
- Dividend Yield
- STRO N/A
- DALN N/A
- EPS Growth
- STRO N/A
- DALN N/A
- EPS
- STRO N/A
- DALN 5.55
- Revenue
- STRO $66,434,000.00
- DALN $123,414,000.00
- Revenue This Year
- STRO N/A
- DALN N/A
- Revenue Next Year
- STRO N/A
- DALN N/A
- P/E Ratio
- STRO N/A
- DALN $2.67
- Revenue Growth
- STRO N/A
- DALN N/A
- 52 Week Low
- STRO $0.52
- DALN $3.25
- 52 Week High
- STRO $5.17
- DALN $16.10
- Technical
- Relative Strength Index (RSI)
- STRO 57.66
- DALN 80.12
- Support Level
- STRO $0.83
- DALN $14.75
- Resistance Level
- STRO $1.01
- DALN $15.00
- Average True Range (ATR)
- STRO 0.07
- DALN 0.18
- MACD
- STRO 0.01
- DALN 0.03
- Stochastic Oscillator
- STRO 51.67
- DALN 49.22
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company. It operates The Dallas Morning News (dallasnews.com), Texas' newspaper. These operations generate revenue from advertising sales within the company's newspaper and digital platforms, subscriptions and retail sales of its newspaper, and commercial printing and distribution services predominantly related to national newspapers. In addition to traditional print and digital advertising, the company has a full-service agency, Medium Giant, offering businesses comprehensive, strategic, and creative marketing solutions. The company's two reportable segments are TDMN and Agency. Maximum revenue is derived from the TDMN segment, which comprises its traditional print business. The firm's customer base is concentrated in North Texas.